Role of hematopoietic growth factors in non-neutropenic infections and sepsis

Current Opinion in Hematology

Volumn 6, Issue 3, 1999, Pages 176-183

  Held, Thomas K ^b   Cross, Alan S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; DESENSITIZATION; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNE RESPONSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SEPSIS; STEM CELL; TISSUE SPECIFICITY;

ANIMALS; BACTERIAL INFECTIONS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; NEUTROPENIA; SEPSIS;

EID: 0032884302     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199905000-00009     Document Type: Article

References (46)

1. 1 Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
2. 2 Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, et al.: Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997, 336:1776-1780.
3. 3 Geller RB: Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996, 14:1371-1382.
4. 4 Lieschke GJ, Burgess AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992, 327:99-106.
5. 5 Granowitz EV, Porat R, Orencole SF, Callahan MV, Lynch EA, Wolff SM, Dinarello CA: Granulocyte-macrophage colony-stimulating factor synthesis during experimental endotoxemia in humans. J Infect Dis 1992, 166:1204-1205.
6. 6 Sallerfors B: Endogenous production and peripheral blood levels of granulocyte-macrophage (GM-) and granulocyte (G-) colony-stimulating factors. Leuk Lymphoma 1994, 13:235-247.
7. 7 Lenhoff S, Olofsson T: Cytokine regulation of GM-CSF and G-CSF secretion by human umbilical cord vein endothelial cells (HUVEC). Cytokine 1996, 8:702-709.
8. 8 Aoki Y, Hirano D, Kodama H, Nishi Y, Nakamura M: Stimulation of G-CSF gene expression in the macrophage cell line by contact with extracellular matrix proteins and a pre-B leukaemia cell line. Cytokine 1998, 8:596-602. Extracellular matrix proteins induced the expression of G-CSF in macrophages as did the direct contact to a G-CSF-dependent leukemia cell line. Both effects could be blocked by pretreatment with monoclonal antibodies against integrins and adhesion molecules. Thus, adhesion itself may activate neutrophils via growth factor expression.
9. 9 Dancey JT, Deubelbeiss KA, Harker LA, Finch CA: Neutrophils kinetics in man. J Clin Invest 1976, 58:705-715.
10. 10 Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C: Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophils leads to its recognition by macrophages. J Clin Invest 1989, 83:865-875.
11. 11 Keel M, Ungethum U, Steckholzer U, Niedere E, Hartung T, Trentz O, Ertel W: Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997, 90:3358-3363. Comparing neutrophils ex vivo from patients with severe sepsis to those from healthy controls, this group demonstrates an anti-apoptotic effect of LPS, TNF-α, G-CSF, GM-CSF, and IFN gamma. This phenomenon was counteracted by IL-10.
12. 12 Karsan A, Yee E, Kaushansky K, Harlan JM: Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood 1996, 87:3089-3096.
13. 13 Chuang PI, Yee E, Karsan A, Winn RK, Harlan JM: A1 is a constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem Biophys Res Commun 1998, 249:361-365. This work provides an explanation on a molecular basis for the anti-apoptotic effects of G-CSF, GM-CSF, and LPS. They demonstrate an upregulation of a Bc1-2 homologue by growth factors and LPS in neutrophils
14. + monocytes.
15. 15 Kunihiro Y, Otsuka T, Niiro H, Arinobu Y, Niho Y, Hamasaki N, Izuhara K: Activation of STAT5 by lipopolysaccharide through granulocyte-macrophage colony-stimulating factor production in human monocytes. J Immunol 1998, 160:838-845. As shown for G-CSF, IL-10 has also a regulatory function in the activation of GM-CSF, LPS led to an increase in GM-CSF production that in turn activated STAT5 and increased expression of inducible cyclooxygenase protein. This was inhibited by IL-10 via suppression of GM-CSF production.
16. 16 Munoz G, Pascual-Salcedo D, del Carmen Castellanous M, Alfranca A, Aragones J, Vara A, et al.: Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: Modulation of NF-κB and AP-1 transcription factors activity. Blood 1996, 88:3482-3490.
17. 17 Salkowski CA, Detore G, Franks A, Falk MC, Vogel SN: Pulmonary and hepatic gene expression following cecal ligation and puncture: monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration. Infect Immun 1998, 66:3569-3578. This study analyzes the complex network of cytokines, growth factors, and adhesion molecules that follows polymicrobial sepsis induced by cecal ligation and puncture. Tissue-specific differences in the expression of three CSFs were observed.
18. 18 Tate RM, Repine JE: Neutrophils and the adult respiratory distress syndrome. Am Rev Respir Dis 1983, 128:552-559.
19. 19 Zhang P, Bagby GJ, Stoltz DA, Spitzer JA, Summer WR, Nelson S: Modulation of the lung host response by granulocyte colony-stimulating factor in rats challenged with intrapulmonary endotoxin. Shock 1997, 7:193-199. Although upregulating CD11b and CD11c expression of circulating neutrophils and increasing their number and phagocytic activity, G-CSF did not exacerbate LPS-induced pulmonary damage, local production of TNF-α, or cytokine-induced neutrophil chemoattractant in rats. However, observation time was short (3 hours), thus not allowing conclusions about possible long-term effects of G-CSF in endotoxin-induced lung injury.
20. 20 Koizumi T, Kubo K, Koyama S, Hanaoka M, Hayano T, Miyahara T, et al.: Neutrophils pretreated with granulocyte colony-stimulating factor (G-CSF) are not related to the severity of endotoxin-induced lung injury. Exp Lung Res 1997, 23:393-404. In this work, no differences in endotoxin-induced lung injury could be detected between the control sheep and the sheep treated additionally with G-CSF, either when G-CSF was given daily for 5 days prior to LPS or when G-CSF was administered in a single dose just before LPS.
21. 21 Kanazawa M, Ishizaka A, Hasegawa N, Suzuki Y, Yokoyama T: Granulocyte colony-stimulating factor does not enhance endotoxin-induced acute lung injury in guinea pigs. Am Rev Respir Dis 1992, 145:1030-1035.
22. 22 Fink MP, O'Sullivan BP, Menconi MJ, Wollert SP, Wang H, Youssef ME, Bellesle JM: Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs. J Trauma 1993, 34:571-578.
23. 23 King J, Deboisblanc BP, Mason CM, Onofrio JM, Lipscomb G, Mercante DE, et al.: Effect of granulocyte colony-stimulating factor on acute lung injury in the rat. Am J Respir Crit Care Med 1995, 151:302-309.
24. 24 Terashima T, Kanazawa M, Sayama K., Ishizaka A, Urano T, Sakamaki F, Nakamura H, Waki Y, Tasaka S: Granulocyte colony-stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs. Am J Respir Crit Care Med 1994, 149:1295-1303.
25. 25 Hanaoka HM, Kubo K, Miyahara T, Hayano T, Koizumi T, Kobayashi T, Sekiguchi M: Effect of post-treatment with granulocyte colony-stimulating factor on endotoxin-induced lung injury in sheep. Exp Lung Res 1998, 24:15-25. Here, the investigators administered G-CSF just after LPS and detected no aggravation in endotoxin-induced lung injury in the treated sheep. G-CSF treatment increased arterial oxygen gas tension and attenuated LPS-induced lung injury.
26. 26 Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995, 86:1301-1309.
27. 27 Held TK, Mielke MEA, Chedid M, Unger M, Trautmann M, Huhn D, Cross AS: Granulocyte colony-stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria. Blood 1998, 91:2525-2535. G-CSF administered before experimental bacterial pneumonia led to dissemination of pulmonary bacteria to distant organs and death by a direct effect on the bacteria. The cytokine bound to bacteria and increased bacterial production of capsular polysaccharide, promoted evasion of phagocytosis and death from overwhelming infection.
28. 28 Dale, DC, Liles WC, Summer WR, Nelson S: Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases. J Infect Dis 1995, 172:1061-1075.
29. 29 Kullberg BJ, Netea MG, Curfs JHAJ, Keuter M, Meis JFGM, van der Meer JWM: Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 1998, 177:175-181. The importance of timing of treatment with G-CSF is emphasized again. Although beneficial when given before or at the time of infection of mice with Candida albicans, G-CSF had no effect on either mortality, growth of microorganisms in various organs, or on histopathologic changes in kidneys.
30. 30 Toki S, Hiromatsu K, Aoki Y, Makino M, Yoshikai Y: Protective effects of granulocyte colony-stimulating factor on endotoxin shock in mice with retrovirus-induced immunodeficiency syndrome. Cytokine 1997, 9:781-786. Again, timing is everything. An interval in G-CSF administration of only 18 hours relative to LPS made the difference between survival after LPS challenge or death. Moreover, suppression of the production of IFN gamma seemed to be one mechanism by which G-CSF exerted its protective effect in LPS-induced shock.
31. 31 Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF: Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998, 42:2467-2473. This careful study provides evidence that with some forms of immunosuppression, G-CSF can be harmful. Although mice made neutropenic with 5-fluorouracil benefited from G-CSF treatment of Aspergillus fumigatus infection, mice immunosuppressed with corticosteroids had the opposite outcome. Moreover, in the latter group, G-CSF strongly antagonized the activity of a new antifungal triazole which, when given alone, reduced fungal growth and prolonged survival.
32. 32 Polak-Wyss A: Protective effect of human granulocyte-colony stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 1991, 34:205-215.
33. 33 Bundschuh DS, Barsig J, Hartung T, Randow F, Docke WD, Volk HD, Wende A: Granulocyte-macrophage colony-stimulating factor and IFN gamma restore the systemic TNF-α response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol 1997, 15:2862-2871. Administration of either GM-CSF or interferon gamma restored the ability of LPS-tolerant mice to produce TNF-α in response to LPS. This was highly time-dependent, however. The effects of interferon gamma and G-SCF on endothelial cell responses differed. They suggest that these two cytokines may overcome sepsis-associated immunosuppression.
34. 34 Teigs G, Barsig J, Matiba B, Uhlig S, Wendel A: Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J Clin Invest 1994, 93:2616-2622.
35. 35 Hacham M, Cristal N, White RM, Segal S, Apte RN: Complementary organ expression of IL-1 versus IL-6 and CSF-1 activities in normal and LPS-injected mice. Cytokine 1996, 8:21-31.
36. 36 Chapoval J, Kamdar SJ, Kremlev SG, Evans R: CSF-1 (M-CSF) differently sensitizes mononuclear phagocyte subpopulations to endotoxin in vivo: a potential pathway that regulates the severity of Gram-negative infections. J Leukoc Biol 1998, 63:245-252.
37. 37 Henricson BE, Neta R, Vogel SN: An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun 1991, 59:1188-1191.
38. 38 Kiani A, Tschiersch A, Gaboriau E, Otto F, Seiz A, Knopf HP, et al.: Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997, 90:1673-1683. Serum levels of G-CSF and IL-6 but not that of pro-inflammatory cytokines were increased in 20 patients with cancer after the administration of a nontoxic LPS analogue. When LPS was given after pretreatment with the LPS analogue, there was a marked reduction in LPS-stimulated release of TNF-α, IL-6, and IL-8 and G-CSF.
39. 39 Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MMC, Jansen J, ten Cate JW, van Deventer SJH: Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997, 90:1415-1424. When G-CSF was given 2 hours before infusion of LPS to human volunteers, there was a shift to a relative anti-inflammatory cytokine response compared to the pro-inflammatory cytokine response with G-CSF pretreatment 24 hour earlier. Despite differences in cytokine response, both regimens reduced pulmonary sequestration of PMNs.
40. 40 Weiss M, Gross-Weege W, Harms B, Schneider EM: Filgrastim (rhG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 1996, 8:260-265.
41. 41 Pollmacher T, Korth C, Schreiber W, Hermann D, Mulligton J: Effects of repeated administration of granulocyte colony-stimulating factor (G-CSF) on neutrophil counts, plasma cytokine, and cytokine receptor levels. Cytokine 1996, 8:799-803.
42. 42 Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, et al., for the CAP Study Group: A randomized controlled trial of Filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998, 178:1075-1080. The Community Acquired Pneumonia (CAP) Study Group found that in this first, large randomized clinical trial with G-CSF in a nonneutropenic patient population, G-CSF treatment did not reduce time to resolution of morbidity, mortality, or length of hospitalization.
43. 43 Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Pharm R, Meyer W, Appelbaum F: Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer. Am J Clin Oncol 1998, 21:341-346. In this retrospective review of patients who underwent autologous bone marrow transplantation, 6 out of 46 (13%) of those who received GM-CSF, versus 38 out of 95 (40%) of those who did not receive this cytokine had infection. They speculate that GM-CSF may enhance the function of tissue macrophages. A prospective, concurrently controlled study is required to confirm this finding.
44. 44 Williams MA, White SA, Miller JJ, Toner C, Withington S, Newland AC, Kelsey SM: Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 1998, 177:107-115. GM-CSF restored the ability of monocytes from septic patients studied ex vivo to respond to stimuli; however, GM-CSF also accelerated tissue factor activation and monocyte procoagulant activity.
45. 45 Kemper CA, Bermudez LE, Deresìnskì SC: Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 1998, 177:914-920.
46. 46 von Reyn CF, Arbeit RD, Tostoson ANA, Ristola MA, Barber TW, Waddell R, et al., and the International MAC Study Group: The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. AIDS 1996, 10:1025-1032.